Brief: Heidelberg Pharma FY Sales Revenue At EUR 7.3 Mln

Heidelberg Pharma AG

19/03/2020 06:11

March 19 (Reuters) - HEIDELBERG PHARMA AG  WL6G.DE :
    * FY SALES REVENUE OF EUR 7.3 MILLION, THUS ALMOST DOUBLING
PRIOR-YEAR FIGURE OF EUR 3.7 MILLION
    * OUTLOOK 2020: EXPECTS TO GENERATE BETWEEN EUR 8.0 MILLION
AND
EUR 10.0 MILLION IN SALES REVENUE AND OTHER INCOME
    * FY EARNINGS BEFORE TAX OF EUR -10.1 MILLION (PREVIOUS
YEAR: EUR
-11.7 MILLION) IN 2019 FISCAL YEAR
    * OUTLOOK 2020: OPERATING EXPENSES ARE EXPECTED TO BE IN
RANGE OF
EUR 20.0 MILLION TO EUR 24.0 MILLIO
    * FY NET LOSS FOR YEAR WAS ALSO EUR 10.1 MILLION (PREVIOUS
YEAR:
EUR 11.7 MILLION)
    * OUTLOOK 2020: OPERATING EXPENSES ARE EXPECTED TO BE IN
RANGE OF
EUR 20.0 MILLION TO EUR 24.0 MILLION
    * EARNINGS BEFORE INTEREST AND TAXES (EBIT) FOR 2020 ARE
EXPECTED
TO BE BETWEEN EUR -11.0 MILLION AND EUR -15.0 MILLION (2019: EUR
-10.1 MILLION)
    * EXPECTS TO REQUIRE FUNDS OF EUR 11.0 MILLION TO EUR 15.0
MILLION
IN 2020
    * GROUP'S FINANCING IS SECURED UNTIL MID-2021 BASED ON
CURRENT
PLANNING
    * PLANNING TAKES INTO ACCOUNT ADDITIONAL POTENTIAL CASH
INFLOWS
FROM NEW LICENSING ACTIVITIES AT HEIDELBERG PHARMA RESEARCH

Source text for Eikon:  ID:nEQ5Xhh84a 
Further company coverage:  WL6G.DE 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 772 0920;;))